Candel's Viral Therapy Targets Glioblastoma with Precision Data

NEEDHAM, MA – February 11, 2026 – As the scientific community converges on Boston for the 7th Annual Glioblastoma Drug Development Summit, Needham-based Candel Therapeutics is poised to take center stage. The company has announced that its Chief Scientific Officer, Dr. Francesca Barone, will present new insights into its promising treatment for recurrent high-grade glioma (rHGG), a notoriously aggressive and difficult-to-treat brain cancer.

The presentations, scheduled for February 17-19, will focus on linoserpaturev (CAN-3110), a novel oncolytic virus therapy. More than just a drug showcase, Candel's agenda signals a deeper strategic focus: leveraging sophisticated biomarker data to unlock the full potential of immunotherapy against a disease that has defied decades of medical advancement.

Unleashing a Virus Against Cancer

Glioblastoma (GBM) remains one of oncology's most formidable challenges. With a median survival of just 15 months after diagnosis and even poorer outcomes for recurrent disease, the need for fundamentally new therapeutic approaches is urgent. Candel’s strategy involves turning one of humanity’s oldest viral foes into a powerful ally.

CAN-3110 is a first-in-class, genetically engineered herpes simplex virus-1 (HSV-1). Designed to be replication-competent, the virus can selectively infect and multiply within cancer cells, ultimately destroying them in a process called oncolysis. But its mechanism is twofold. As the virus breaks the tumor cells apart, it releases tumor-associated antigens and viral components, effectively sounding an alarm that recruits the body's own immune system to the site of the cancer. This process aims to transform the tumor microenvironment from an "immune desert"—a common feature of glioblastoma that allows it to evade detection—into a hotbed of anti-tumor activity.

This dual-action approach of direct cell killing and systemic immune activation is what separates oncolytic immunotherapies from many traditional treatments. For a cancer as resilient and complex as glioblastoma, a multi-pronged attack may be the only way to achieve a durable response.

Promising Signals from the CAN-3110 Program

The anticipation surrounding Candel’s summit presentations is built on a foundation of compelling, peer-reviewed clinical data. An ongoing Phase 1b clinical trial of CAN-3110 in patients with recurrent high-grade glioma has already yielded significant findings, providing a glimpse of the therapy's potential.

Results published in the prestigious journal Nature in October 2023 reported that a single injection of CAN-3110 was generally well-tolerated and, more importantly, was associated with an improved median overall survival of 11.8 months. This figure stands in stark contrast to the historical survival of less than nine months for this patient population, offering a tangible measure of hope. The study linked this extended survival to a robust anti-tumor response, noting a significant increase in immune cells within the tumor microenvironment following treatment.

Further analysis published in Science Translational Medicine in October 2025 delved deeper, examining serial tumor biopsies from patients who received repeated doses of the virus. The findings confirmed that CAN-3110 could successfully remodel the tumor's defenses and trigger a specific T-cell response against it. These results have been bolstered by regulatory recognition; the U.S. Food and Drug Administration (FDA) has granted linoserpaturev both Fast Track and Orphan Drug designations, underscoring the therapy's potential to address a critical unmet medical need.

The Biomarker Blueprint: A Strategy for Precision

While the science behind CAN-3110 is compelling, Candel's focus at the upcoming summit reveals its true strategy: precision. Glioblastoma is not a monolithic disease; it is characterized by profound molecular heterogeneity between patients and even within a single tumor. This diversity is a primary reason why one-size-fits-all therapies often fail.

Dr. Barone’s scheduled presentations—titled "Harnessing Omics Data & Molecular Subtyping," "Integration of Biomarkers & Imaging," and "Driving the Use of Biomarker-Based Enrollment"—point directly to Candel's plan to tackle this heterogeneity head-on. The company is not just developing a drug; it is developing a blueprint for its intelligent application.

By integrating 'omics data (genomics, proteomics, etc.), advanced imaging, and molecular subtyping, Candel aims to identify which patients are most likely to respond to CAN-3110. This biomarker-driven approach has two key benefits. First, it can increase the likelihood of success in clinical trials by enrolling patients with the most favorable biological profiles. Second, and more importantly, it promises a future where glioblastoma treatment is personalized, sparing non-responsive patients from ineffective therapies and maximizing the benefit for those who can truly be helped. This represents a significant shift toward precision oncology for one of medicine’s most challenging fields.

Navigating a Competitive and Financial Landscape

Candel Therapeutics is advancing its platform in a dynamic and competitive field. Several other biopharmaceutical companies are pursuing oncolytic viruses for glioblastoma, using different viral backbones such as adenovirus and poliovirus. However, Candel's strong clinical data and sophisticated biomarker strategy appear to be resonating with investors and analysts.

The company (Nasdaq: CADL) holds a "Strong Buy" consensus rating from market analysts, with some price targets projecting an upside of over 200% from its current trading price. This optimism is fueled not only by the potential of CAN-3110 but also by the success of Candel's other lead candidate, aglatimagene besadenovec (CAN-2409), which has shown positive results in prostate, pancreatic, and non-small cell lung cancer trials.

Crucially, Candel appears to have the financial endurance for the long road of drug development. With a reported cash runway extending into early 2027 and a recently secured debt facility, the company is well-capitalized to advance its ambitious pipeline. The upcoming presentations at the Glioblastoma Drug Development Summit will be a key test, offering a platform to reinforce investor confidence and further differentiate Candel’s methodical, data-driven approach in the high-stakes race to develop a meaningful therapy for brain cancer.